Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-Outcomes in high-risk MASLD
MOH_2026-01-07_015590Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Retatrutide or placebo with Tirzepatide or placebo (2 arms). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on MOH_2026-01-07_015590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-07_015590.